Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Neurological Biomarkers Market, by Type
1.4.2 Europe Neurological Biomarkers Market, by Application
1.4.3 Europe Neurological Biomarkers Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenarios
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Neurological Biomarkers Market by Type
3.1 Europe Proteomic Market by Country
3.2 Europe Genomic Market by Country
3.3 Europe Metabolomic Market by Country
3.4 Europe Others Market by Country
Chapter 4. Europe Neurological Biomarkers Market by Application
4.1 Europe Alzheimer's Disease Market by Country
4.2 Europe Parkinson’s Disease Market by Country
4.3 Europe Multiple Sclerosis Market by Country
Chapter 5. Europe Neurological Biomarkers Market by Country
5.1 Germany Neurological Biomarkers Market
5.1.1 Germany Neurological Biomarkers Market by Type
5.1.2 Germany Neurological Biomarkers Market by Application
5.2 UK Neurological Biomarkers Market
5.2.1 UK Neurological Biomarkers Market by Type
5.2.2 UK Neurological Biomarkers Market by Application
5.3 France Neurological Biomarkers Market
5.3.1 France Neurological Biomarkers Market by Type
5.3.2 France Neurological Biomarkers Market by Application
5.4 Russia Neurological Biomarkers Market
5.4.1 Russia Neurological Biomarkers Market by Type
5.4.2 Russia Neurological Biomarkers Market by Application
5.5 Spain Neurological Biomarkers Market
5.5.1 Spain Neurological Biomarkers Market by Type
5.5.2 Spain Neurological Biomarkers Market by Application
5.6 Italy Neurological Biomarkers Market
5.6.1 Italy Neurological Biomarkers Market by Type
5.6.2 Italy Neurological Biomarkers Market by Application
5.7 Rest of Europe Neurological Biomarkers Market
5.7.1 Rest of Europe Neurological Biomarkers Market by Type
5.7.2 Rest of Europe Neurological Biomarkers Market by Application
Chapter 6. Company Profiles
6.1 F. Hoffmann-La Roche Ltd.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Bio-Rad laboratories, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expenses
6.3 Merck Group
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Partnerships, Collaborations, and Agreements:
6.4 PerkinElmer, Inc.
6.4.1 Company Overview
6.4.1 Financial Analysis
6.4.2 Segmental and Regional Analysis
6.4.3 Research & Development Expense
6.5 Shimadzu Corporation
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.6 Thermo Fisher Scientific, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 BioMérieux S.A.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Segmental and Regional Analysis
6.7.4 Research & Development Expenses
6.8 Myriad Genetics, Inc.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental Analysis
6.8.4 Research & Development Expenses
6.9 Quanterix Corporation
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.9.5 Recent strategies and developments:
6.9.5.1 Partnerships, Collaborations, and Agreements:
6.10. Neuro-Bio Ltd.
6.10.1 Company Overview
Unique Offerings 